Codexis (CDXS) Cash from Investing Activities (2010 - 2026)
Codexis (CDXS) posted quarterly Cash from Investing Activities of -$1.1 million for Q1 2026, down 109.44% year-over-year from $11.8 million in Q1 2025, and down 119.45% quarter-over-quarter from $5.7 million in Q4 2025.
Codexis (CDXS) Cash from Investing Activities (2010 - 2026) Analysis & Trends
Codexis' Cash from Investing Activities history runs 17 years deep, the most recent figure standing at -$1.1 million for Q1 2026.
- In Q1 2026, Cash from Investing Activities fell 109.44% year-over-year to -$1.1 million; the TTM figure through Mar 2026 stood at $10.6 million (up 163.8% YoY), while the FY2025 annual figure was $23.5 million, up 141.25% from the prior year.
- Cash from Investing Activities for Q1 2026 stood at -$1.1 million, down from $5.7 million in the prior quarter.
- The five-year high for Cash from Investing Activities was $11.8 million in Q1 2025, with the low at -$28.6 million in Q1 2024.
- The 5-year median for Cash from Investing Activities is -$1.1 million (2026), against an average of -$3.1 million.
- The sharpest annual moves came in 2023 and 2024: Cash from Investing Activities jumped 3245.45% in 2023, then sank 1624.19% in 2024.
- Codexis' Cash from Investing Activities stood at $33000.0 in 2022, then surged by 3245.45% to $1.1 million in 2023, then sank by 359.33% to -$2.9 million in 2024, then surged by 299.55% to $5.7 million in 2025, then tumbled by 119.45% to -$1.1 million in 2026.
- Business Quant data shows CDXS's Cash from Investing Activities at -$1.1 million in Q1 2026, $5.7 million in Q4 2025, and $6.4 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | -45.80 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | -92.70 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 329.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | -49.35 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | -363.46 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -3.17 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 24.51 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | -229.72 Mn |
| 10 | Codexis | 152.06 Mn | 97.14 Mn | 11.40 Mn | 175,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 175,000.00 |
| Jun 30, 2026 | 175,000.00 |
| Mar 31, 2026 | -1.11 Mn |
| Mar 31, 2026 | -1.11 Mn |
| Dec 31, 2025 | 5.71 Mn |
| Dec 31, 2025 | 5.71 Mn |
| Sep 30, 2025 | 6.39 Mn |
| Sep 30, 2025 | 6.39 Mn |
| Jun 30, 2025 | -367,000.00 |
| Jun 30, 2025 | -367,000.00 |
| Mar 31, 2025 | 11.77 Mn |
| Mar 31, 2025 | 11.77 Mn |
| Dec 31, 2024 | -2.86 Mn |
| Dec 31, 2024 | -2.86 Mn |
| Sep 30, 2024 | 1.53 Mn |
| Sep 30, 2024 | 1.53 Mn |
| Jun 30, 2024 | -27.09 Mn |
| Jun 30, 2024 | -27.09 Mn |
| Mar 31, 2024 | -28.56 Mn |
| Mar 31, 2024 | -28.56 Mn |